CDChristopher Clement Denton

Christopher Clement Denton

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Christopher Clement Denton has a total of 441 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Guideline Adherence for Vaso-Occlusive Pain Episode Treatment for Children and Young Adults with Sickle Cell Disease

    by Chris A. Rees, Rawan Korman, Dunia Hatabah, Fahd A. Ahmad, Gladstone Airewele, Bolanle Akinsola, Noor Alzraikat, Nitya Bakshi, David C. Brousseau, Kathleen Brown, et al.

  • Successful Use of Sutimlimab in two Pediatric Patients With Refractory Cold Antibody‐Mediated Autoimmune Hemolytic Anemia

    by Sibgha Zaheer, Rachel Friedmann, Kimberly Cheng, Guy Young, Christopher Denton, Taylor Kim

    Cold antibody‐mediated autoimmune hemolytic anemia, or cold agglutinin syndrome (CAS), in pediatrics is typically transient, although it can often be severe and require transfusion support. Recurrence in children is rare, but those with underlying immune dysfunction can have a refractory course with limited options available. We report a 4‐year‐old girl with Evans syndrome and life‐threatening CAS refractory to transfusions, plasmapheresis, steroids, and immunosuppression as well as a 12‐month‐old boy status post liver transplant with CAS refractory to steroids, rituximab, and tacrolimus cessation with transition to sirolimus, both of whom received sutimlimab, a C1s inhibitor, with rapid improvement in hemolysis, transfusion independence, and a sustained remission. To our knowledge, these are the first reported uses of sutimlimab in the pediatric population.


  • Open Access

    Chronic Anemia Is Associated With Subclinical Myocardial Fibrosis in α‐Τhalassemia Intermedia

    by Karen S. Kim, Saranya Veluswamy, John C. Wood, Thomas D. Coates, Christopher C. Denton

  • Hospital Variations in Time‐To‐Crisis‐Resolution Among Children and Adolescents With Sickle Cell Disease

    by Chris A. Rees, Dunia Hatabah, Rawan Korman, Fahd Ahmad, Gladstone Airewele, Bolanle Akinsola, Noor Alzraikat, Nitya Bakshi, David C. Brousseau, Kathleen Brown, et al.

    Analysis of the placebo cohort in the STArT trial shows that patient characteristics and hospital site strongly influence time-to-crisis-resolution and total opioid use in children and young adults with sickle cell disease, highlighting the need to account for these factors in the design of future clinical trials.


  • Transfusional hemosiderosis in childhood cancer patients and survivors

    by Jacquelyn Baskin‐Miller, Susan Carson, Julie Jaffray, Craig Fletcher, Jessie Singer, David R. Freyer, John Wood, Thomas D. Coates, Christopher C. Denton

    Background: Children treated for cancer are at risk for adverse effects of iron due to transfusions administered during prolonged marrow suppression, which may increase exposure to toxic forms of iron, extrahepatic iron accumulation, and long‐term organ damage.Objective: This study aimed to characterize the severity and organ distribution of clinically significant, multisystem iron overload (IO) in an at‐risk cohort of pediatric cancer patients.Methods: This was a retrospective, cross‐sectional study of childhood cancer patients who underwent a magnetic resonance imaging (MRI) due to clinical concern for IO. Data regarding cancer type and treatment, transfusion history, MRI and laboratory results, and treatment for IO were collected. Severity of IO was analyzed by non‐parametric tests with respect to clinical characteristics.Results: Of the 103 patients, 98% of whom had a Cancer Intensity Treatment Rating (ITR‐3) of 3 or higher, 53% (54/102) had moderate or greater hepatic siderosis, 80% (77/96) had pancreatic siderosis, 4% (3/80) had cardiac siderosis, and 45% (13/29) had pituitary siderosis and/or volume loss. Pancreatic iron was associated with both cardiac (p = .0043) and pituitary iron (p = .0101). In the 73 off‐therapy patients, ferritin levels were lower (p = .0008) with higher correlation with liver iron concentration (LIC) (p = .0016) than on‐therapy patients. Fifty‐eight subjects were treated for IO.Conclusion: In this heavily treated cohort of pediatric cancer patients, more than 80% had extrahepatic iron loading, which occurs with significant exposure to toxic forms of iron related to decreased marrow activity in setting of transfusions. Further studies should examine the effects of exposure to reactive iron on long‐term outcomes and potential strategies for management.


  • Open Access

    Transfusional Hemosiderosis in Childhood Cancer Patients and Survivors

    by Jacquelyn Baskin, Susan Carson, Julie Jaffray, David Freyer, John Wood, Thomas Coates, Christopher Denton

    Background: Children treated for cancer are at risk of developing iron toxicity due to receiving red cell transfusions and myelosuppressive chemotherapy. Transfusions administered during prolonged episodes of marrow suppression may increase exposure to toxic, reactive forms of iron and thereby increase risk of extrahepatic iron accumulation and long-term organ damage. Objective: This study aimed to evaluate the severity and organ distribution of clinically significant iron overload through measurement of hepatic, cardiac, pancreatic, and pituitary iron deposition in an at-risk cohort of children and young adults treated for cancer. Methods: This retrospective study evaluated patients treated for any type of cancer who underwent an MRI due to clinical concern for evaluation of iron overload (n=103, 73 post-treatment). Data regarding cancer type and treatment, MRI and laboratory results, and treatment for iron overload were analyzed. Results: Over half (53%) of this sample had moderate or greater hepatic siderosis, 80% had pancreatic siderosis, and nearly half (45%) had pituitary siderosis and/or volume loss. Pancreatic iron was associated with both cardiac (p=0.0043) and pituitary iron (p=0.0101). Patients treated for acute myeloid leukemia or high-risk acute lymphoblastic leukemia had higher liver iron concentration (LIC) compared to other cancer types (median LIC 8.5 vs. 2.9 mg/g DLW, p=0.0011). Conclusion: Pediatric cancer patients are at risk for transfusional iron overload, with significant exposure to toxic forms of iron indicated by extrahepatic iron deposition (pancreas, heart and pituitary). Further studies should examine the effect of exposure to reactive iron on long-term outcomes and develop management recommendations.

  • Splenic iron decreases without change in volume or liver parameters during luspatercept therapy

    by Christopher C. Denton, Sadanand Vodala, Saranya Veluswamy, Thomas C. Hofstra, Thomas D. Coates, John C. Wood

    Splenic iron decreased whereas liver iron was stable during luspatercept therapy in some individuals with thalassemia. This suggests a reduction of ineffective erythropoiesis changes the organ distribution of iron and demonstrates that liver iron concentration alone may not accurately reflect total body iron content. This article describes data from subjects enrolled in BELIEVE (NCT02604433) and BEYOND (NCT03342404).


  • Table of Contents

    by Rebekka Jerjen, Mandana Nikpour, Thomas Krieg, Christopher Denton, Amanda Saracino, Dirk M. Elston, Brett Sloan, Jonathan Kantor, Erin M. Warshaw, Jenna L. Ruggiero, et al.

  • Open Access

    Loss of alpha globin genes is associated with improved microvascular function in patients with sickle cell anemia

    by Marc Romana, Karen Reminy, Berenike Moeckesch, Keyne Charlot, Marie‐Dominique Hardy‐Dessources, Lydia Doumdo, Benoit Tressieres, Maryse Etienne‐Julan, Nathalie Lemonne, Christopher Denton, et al.


  • Loss of alpha‐globin genes in human subjects is associated with improved nitric oxide‐mediated vascular perfusion

    by Christopher C. Denton, Payal Shah, Silvie Suriany, Honglei Liu, Wanwara Thuptimdang, John Sunwoo, Patjanaporn Chalacheva, Saranya Veluswamy, Roberta Kato, John C. Wood, et al.

    Alpha thalassemia is a hemoglobinopathy due to decreased production of the α‐globin protein from loss of up to four α‐globin genes, with one or two missing in the trait phenotype. Individuals with sickle cell disease who co‐inherit the loss of one or two α‐globin genes have been known to have reduced risk of morbid outcomes, but the underlying mechanism is unknown. While α‐globin gene deletions affect sickle red cell deformability, the α‐globin genes and protein are also present in the endothelial wall of human arterioles and participate in nitric oxide scavenging during vasoconstriction. Decreased production of α‐globin due to α‐thalassemia trait may thereby limit nitric oxide scavenging and promote vasodilation. To evaluate this potential mechanism, we performed flow‐mediated dilation and microvascular post‐occlusive reactive hyperemia in 27 human subjects (15 missing one or two α‐globin genes and 12 healthy controls). Flow‐mediated dilation was significantly higher in subjects with α‐trait after controlling for age (P = .0357), but microvascular perfusion was not different between groups. As none of the subjects had anemia or hemolysis, the improvement in vascular function could be attributed to the difference in α‐globin gene status. This may explain the beneficial effect of α‐globin gene loss in sickle cell disease and suggests that α‐globin gene status may play a role in other vascular diseases.